Company Description
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins.
Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers.
It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life.
Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators.
The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Country | CH |
IPO Date | Jun 16, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 167 |
CEO | Dr. Patrick Amstutz Ph.D. |
Contact Details
Address: Wagistrasse 14 Schlieren, CH | |
Website | https://www.molecularpartners.com |
Stock Details
Ticker Symbol | MOLN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001745114 |
CUSIP Number | 60853G106 |
ISIN Number | US60853G1067 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Patrick Amstutz Ph.D. | Co-Founder, Chief Executive Officer, Member of Management Board & Director |
Alexander Zurcher | Chief Operating Officer & Member of Management Board |
Anne Goubier D.V.M., Ph.D. | Senior Vice President of Research & Early Development |
Daniel Steiner Ph.D. | Senior Vice President of Research & Technology |
Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive Vice President of Projects & Member of Management Board |
Dr. Pamela A. Trail Ph.D. | Strategic Consultant |
Michael Pitzner | General Counsel, Compliance Officer, Senior Vice President Legal & Business Development |
Renate Gloggner | Executive Vice President of People & Community and Member of Management Board |
Robert Hendriks | Senior Vice President of Finance |
Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 31, 2024 | 6-K | Filing |
Oct 29, 2024 | SC 13D/A | [Amend] Filing |
Oct 28, 2024 | 6-K | Filing |
Oct 25, 2024 | 424B5 | Filing |
Oct 22, 2024 | 6-K | Filing |
Aug 26, 2024 | 6-K | Filing |
Jun 26, 2024 | S-8 | Filing |
Jun 14, 2024 | 6-K | Filing |
Jun 11, 2024 | 6-K | Filing |
Jun 03, 2024 | 6-K | Filing |